The US Food and Drug Administration (FDA) has approved Boston Scientific’s Vercise Deep Brain Stimulation (DBS) System for the treatment of Parkinson’s disease symptoms.

A DBS system is designed to trigger a targeted region of the brain through implanted leads powered by a device called implantable pulse generator (IPG).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The small, rechargeable Vercise system features a capability to independently regulate the amount of current to be delivered by each electrode on the implanted leads.

This adaptable stimulation delivery is intended to address symptom fluctuations of the disease and its progressive nature.

The Vercise system leads come with eight contacts having a total span of 15.5mm and tight spacing between contacts of 0.5mm with multi-lumen construction.

“Our system stands apart from the field in its approach and is changing the traditional definition on how we can leverage technology to treat patients with Parkinson’s disease.”

Boston Scientific Neuromodulation president and senior vice-president Maulik Nanavaty said: “This approval marks an important step for patients who will now have the choice to be treated with one of the most innovative neuromodulation technologies available today.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Our system stands apart from the field in its approach and is changing the traditional definition on how we can leverage technology to treat patients with Parkinson’s disease.”

The FDA approval is based on the positive findings from the multi-centre, prospective, double-blind, randomised sham-controlled INTREPID study conducted in 292 subjects at 23 centres in the country.

These results were supported by safety data obtained during the multi-centre, prospective, single-arm VANTAGE trial in 40 European patients.

Boston Scientific intends to carry out the first commercial implant using the Vercise System at the University of Minnesota Medical Centre in Minneapolis, US.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact